tbuckley/cabot-search huggingface dataset:
Association Between Quantitative Sialoscintigraphy and Antibody Profiles in Patients With Sjögren or Sicca Syndrome
Authors: Tzyy-Ling Chuang, Malcolm Koo, Yi-Min Lee, Chien-Hsueh Tung, Yuh-Feng Wang
Journal: Clinical Nuclear Medicine (2024)

This study analyzed the association between anti-Ro/SSA and anti-La/SSB antibody levels with quantitative and visual sialoscintigraphy patterns in patients suspected of having Sjögren or sicca syndrome.
Opportunities and challenges of single-cell and spatially resolved genomics methods for neuroscience discovery
Authors: Boyan Bonev, Castelo-Branco Gonçalo, Fei Chen, Simone Codeluppi, M. Ryan Corces, Jean Fan, Myriam Heiman, Kenneth Harris, Fumitaka Inoue, Manolis Kellis, Ariel Levine, Mo Lotfollahi, Chongyuan Luo, Kristen R. Maynard, Mor Nitzan, Vijay Ramani, Rahul Satijia, Lucas Schirmer, Yin Shen, Na Sun, Gilad S. Green, Fabian Theis, Xiao Wang, Joshua D. Welch, Ozgun Gokce, Genevieve Konopka, Shane Liddelow, Evan Macosko, Omer Bayraktar, Naomi Habib, Tomasz J. Nowakowski
Journal: Nature Neuroscience (2024)
Publication Pressure in Nuclear Medicine
Authors: Thomas C. Kwee, Ali Aldub, Robert M. Kwee
Journal: Clinical Nuclear Medicine (2024)

Purpose The aims of this study were to determine the publication pressure perceived by nuclear medicine scientists and to identify associated determinants. Patients and Methods Corresponding authors who published in Clinical Nuclear Medicine , Journal of Nuclear Medicine , or European Journal of Nuclear Medicine and Molecular Imaging between 2021 and 2023 were invited to participate in this survey study. Publication pressure was assessed using the revised Publication Pressure Questionnaire in the domains of “publication stress” (stress due to perceived pressure to publish), “publication attitude” (attitude regarding current publication culture), and “publication resources” (resources when working on publications or experiencing stress when working on publishing), with 5-point Likert scales. Results A total of 181 individuals participated. Median Publication Pressure Questionnaire scores in the domains “publication stress,” “publication attitude,” and “publication resources” were 3.33, 3.33, and 2.17, respectively. None of the researchers’ characteristics were significantly associated with publication stress. Age &gt;65 years was significantly associated with a more positive view on the publication climate (β coefficient of −0.552, P = 0.007). Several variables were significantly associated with a perception of fewer factors available to alleviate publication pressure: age 45–54 years (β coefficient of 0.249, P = 0.030), age 55–64 years (β coefficient of 0.421, P = 0.002), associate professor position (β coefficient of 0.398, P &lt; 0.001), fellow/resident position (β coefficient of 0.355, P = 0.007), &lt;5 years of research experience (β coefficient of 0.410, P = 0.026), and 5–10 years of research experience (β coefficient of 0.361, P = 0.003). Conclusions Publication pressure among nuclear medicine scientists is appreciable. Several researcher characteristics appear to be associated with vulnerability to publication pressure.
Clinical characteristics and outcome of central nervous system tumors harboring NTRK gene fusions
Authors: Audrey-Anne Lamoureux, Michael J. Fisher, Lauriane Lemelle, Elke Pfaff, Pouneh Amir-Yazdani, Christof Kramm, Bram De Wilde, Bernarda Kazanowska, Caroline Hutter, Stefan M. Pfister, Dominik Sturm, David T.W. Jones, Daniel Orbach, Gaëlle Pierron, Scott Raskin, Alexander Drilon, Eli L. Diamond, Guilherme Harada, Michal Zapotocky, Josef Zamecnik, Lenka Krskova, Benjamin Ellezam, Alexander G. Weil, Dominic Venne, Marc Barritault, Pierre Leblond, Hallie Coltin, Rawan Hammad, Uri Tabori, Cynthia Hawkins, Jordan R. Hansford, Deborah Meyran, Craig Erker, Kathryn McFadden, Mariko Sato, Nicholas G. Gottardo, Hetal Dholaria, Dorte Schou. Nørøxe, Hiroaki Goto, David S. Ziegler, Frank Y. Lin, Donald Williams. Parsons, Holly Lindsay, Tai-Tong Wong, Yen-Lin Liu, Kuo-Sheng Wu, Andrea T. Franson, Eugene Hwang, Ana Aguilar-Bonilla, Sylvia Cheng, Chantel Cacciotti, Maura Massimino, Elisabetta Schiavello, Paul Wood, Lindsey M. Hoffman, Andréa Cappellano, Alvaro Lassaletta, An Van Damme, Anna Llort, Nicolas U. Gerber, Mariella Spalato Ceruso, Anne E. Bendel, Maggie Skrypek, Dima Hamideh, Naureen Mushtaq, Andrew Walter, Nada Jabado, Aysha Alsahlawi, Jean-Pierre Farmer, Christina Coleman, Sabine Mueller, Claire Mazewski, Dolly Aguilera, Nathan J. Robison, Katrina O’Halloran, Samuel Abbou, Pablo Berlanga, Birgit Geoerger, Ingrid Øra, Christopher L. Moertel, Evangelia D. Razis, Anastasia Vernadou, François Ducray, Charlotte Bronnimann, Romuald Seizeur, Matthew Clarke, Adam C. Resnick, Mélanie Alves, Chris Jones, François Doz, Theodore W. Laetsch, Sébastien Perreault
Journal: Clinical Cancer Research (2024)

Abstract Purpose: TRK fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental design: We conducted an international retrospective cohort study of patients with TRK fusion-driven CNS tumors. Results: 119 patients were identified. The median age at time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG) (57.1%) followed by low-grade glioma (LGG) (27.7%). Pediatric patients had a better prognosis with a median overall survival of 185.5 months compared to 24.8 months in adults (p&amp;lt;.0001). Patients with LGG also had a better outcome when compared to HGG (p=0.0012). The objective response was 68.8% with larotrectinib compared to 38.1% for non-targeted treatment. Conclusions: Children with LGG glioma had a favorable outcome compared to adult and HGG. TRK inhibitors appear to improve tumor control.
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO
Authors: A Raimondi, S Lonardi, S Murgioni, G G Cardellino, S Tamberi, A Strippoli, F Palermo, G De Manzoni, M Bencivenga, A Bittoni, C Chiodoni, D Lorenzini, K Todoerti, P Manca, S Sangaletti, M Prisciandaro, G Randon, F Nichetti, F Bergamo, S Brich, A Belfiore, A Bertolotti, D Stetco, A Guidi, T Torelli, A Vingiani, R P Joshi, M Khoshdeli, N Beaubier, M C Stumpe, F Nappo, A G Leone, C C Pircher, G Leoncini, G Sabella, L Airo' Farulla, A Alessi, F Morano, A Martinetti, M Niger, M Fassan, M Di Maio, K Kaneva, M Milione, H Nimeiri, C Sposito, L Agnelli, V Mazzaferro, M Di Bartolomeo, F Pietrantonio
Journal: Annals of Oncology (2024)
18F-FDG PET/CT Imaging of Myoepithelial Carcinoma in the Left Femur
Authors: Shuhui Huang, Hangyu Xie, Rui Huang
Journal: Clinical Nuclear Medicine (2024)

Abstract Myoepithelial carcinoma of bone is uncommon. We presented the imaging features of myoepithelial carcinoma of the left femur in a 61-year-old man on 18 F-FDG PET/CT. Lytic bone destruction and the formation of a slightly low-density soft tissue mass extending to adjacent muscles with intense and circular FDG uptake were found on 18 F-FDG PET/CT. Postoperative pathology confirmed the diagnosis of myoepithelial carcinoma.
18F-AlF-NOTA-FAPI-04 Superior to 18F-FDG PET/CT in Detecting Primary Tumor and Metastatic Lymph Nodes in a Cervical Cancer Patient
Authors: Jinhui Wei, Qiaochu Feng, Haodong Liu, Hongna Zheng, Longjie Li
Journal: Clinical Nuclear Medicine (2024)

A 41-year-old woman with an enlarged right supraclavicular lymph node underwent a fine-needle biopsy, which confirmed the presence of metastatic squamous cell carcinoma. To identify the primary tumor, an 18 F-FDG PET/CT scan was performed, revealing multiple metabolically active lymph nodes throughout the body, but no primary lesion was identified. Subsequently, an 18 F-AlF-NOTA-FAPI-04 PET/CT scan was conducted, which demonstrated increased abnormal uptake in the cervix and revealed additional metabolically active lymph nodes. Thus, a biopsy of the uterine cervical region was performed, and the results confirmed cervical squamous cell carcinoma.
Author correction to ‘Up-regulation of glycolipid transfer protein by bicyclol causes spontaneous restriction of hepatitis C virus replication’ [Acta Pharmaceutica Sinica B 9 (2019) 769-781].
Authors: Menghao Huang, Hu Li, Rong Xue, Jianrui Li, Lihua Wang, Junjun Cheng, Zhouyi Wu, Wenjing Li, Jinhua Chen, Xiaoqin Lv, Qiang Li, Pei Lan, Limin Zhao, Yongfeng Yang, Zonggen Peng, Jiandong Jiang
Journal: Acta Pharmaceutica Sinica B (2024)

[This corrects the article DOI: 10.1016/j.apsb.2019.01.013.].
The Society for Immunotherapy of Cancer Perspective on Tissue-Based Technologies for Immuno-Oncology Biomarker Discovery and Application
Authors: Anne Monette, Adriana Aguilar-Mahecha, Emre Altinmakas, Mathew G. Angelos, Nima Assad, Gerald Batist, Praveen K. Bommareddy, Diana L. Bonilla, Christoph H. Borchers, Sarah E. Church, Gennaro Ciliberto, Alexandria P. Cogdill, Luigi Fattore, Nir Hacohen, Mohammad Haris, Vincent Lacasse, Wen-Rong Lie, Arnav Mehta, Marco Ruella, Houssein Abdul Sater, Alan Spatz, Bachir Taouli, Imad Tarhoni, Edgar Gonzalez-Kozlova, Itay Tirosh, Xiaodong Wang, Sacha Gnjatic
Journal: Clinical Cancer Research (2024)

Abstract With immuno-oncology becoming the standard of care for a variety of cancers, identifying biomarkers that reliably classify patient response, resistance, or toxicity becomes the next critical barrier toward improving care. Multiparametric, multi-omics, and computational platforms generating an unprecedented depth of data are poised to usher in the discovery of increasingly robust biomarkers for enhanced patient selection and personalized treatment approaches. Deciding which developing technologies to implement in clinical settings ultimately, applied either alone or in combination, relies on weighing pros and cons, from minimizing patient sampling to maximizing data outputs, and assessing the reproducibility and representativeness of findings, while lessening data fragmentation toward harmonization. These factors are all assessed while taking into consideration the shortest turnaround time. The Society for Immunotherapy of Cancer Biomarkers Committee convened to identify important advances in biomarker technologies and to address advances in biomarker discovery using multiplexed IHC and immunofluorescence, their coupling to single-cell transcriptomics, along with mass spectrometry–based quantitative and spatially resolved proteomics imaging technologies. We summarize key metrics obtained, ease of interpretation, limitations and dependencies, technical improvements, and outward comparisons of these technologies. By highlighting the most interesting recent data contributed by these technologies and by providing ways to improve their outputs, we hope to guide correlative research directions and assist in their evolution toward becoming clinically useful in immuno-oncology.
The senotherapeutic potential of phytochemicals for age-related intestinal disease
Authors: Célia Maria Costa, Sílvia Santos Pedrosa, James L Kirkland, Flávio Reis, Ana Raquel Madureira
Journal: Ageing Research Reviews (2024)

During the last few decades, life expectancy has increased worldwide along with the prevalence of several age-related diseases. Among aging pathways, cellular senescence and chronic inflammation (or "inflammaging") appear to be connected to gut homeostasis and dysbiosis of the microbiome. Cellular senescence is a state of essentially irreversible cell cycle arrest that occurs in response to stress. Although senescent cells (SC) remain metabolically active, they do not proliferate and can secrete inflammatory and other factors comprising the senescence-associated secretory phenotype (SASP). Accumulation of SCs has been linked to onset of several age-related diseases, in the brain, bones, the gastrointestinal tract, and other organs and tissues. The gut microbiome undergoes substantial changes with aging and is tightly interconnected with either successful (healthy) aging or disease. Senotherapeutic drugs are compounds that can clear senescent cells or modulate the release of SASP factors and hence attenuate the impact of the senescence-associated pro-inflammatory state. Phytochemicals, phenolic compounds and terpenes, which have antioxidant and anti-inflammatory activities, could also be senotherapeutic given their ability to act upon senescence-linked cellular pathways. The aim of this review is to dissect links among the gut microbiome, cellular senescence, inflammaging, and disease, as well as to explore phytochemicals as potential senotherapeutics, focusing on their interactions with gut microbiota. Coordinated targeting of these inter-related processes might unveil new strategies for promoting healthy aging.
Erratum to ‘The neuroprotective effect of traditional Chinese medicinal plants—A critical review’ [Acta Pharmaceutica Sinica B 13 (2023) 3208-3237]
Authors: João Moreira, Mariana Machado, Mónica Dias-Teixeira, Ricardo Ferraz, Cristina Delerue-Matos, Clara Grosso
Journal: Acta Pharmaceutica Sinica B (2024)
Long-term evolution of prepubertal-onset anogenital lichen sclerosus: A 35-year retrospective and cross-sectional study from a single tertiary care maternal and pediatric center
Authors: Sheila Vallée, Violaine Deneux, Deana Funaro, Danielle Marcoux, Julie Powell, Afshin Hatami, Jérôme Coulombe, Maryam Piram, Catherine Cameron McCuaig
Journal: Journal of the American Academy of Dermatology (2024)
ST2+ T-Regulatory Cells as a Potential Immunotherapy Target for Kidney Fibrosis
Authors: Allison E. Norlander, David P. Basile
Journal: Journal of the American Society of Nephrology (2024)

Department of Anatomy, Cell Biology and Physiology, Indiana University of Medicine, Indianapolis, Indiana Correspondence: Dr. David P. Basile, email: [email protected] See related article, "ST2+ T-Regulatory Cells in Renal Inflammation and Fibrosis after Ischemic Kidney," on pages XXX–XXX.
Need to Advance Pain Management in Kidney Failure beyond Opioid Medications
Authors: Kirsten L. Johansen
Journal: Journal of the American Society of Nephrology (2024)

Department of Medicine, Hennepin Healthcare Research Institute, University of Minnesota, Minneapolis, Minnesota Correspondence: Dr. Kirsten L. Johansen, email: [email protected] See related article, "Opioid Prescriptions for US Patients Undergoing Long-Term Dialysis or with Kidney Transplant from 2011 to 2020," on pages XXX–XXX.
Disparities in Care
Authors: Jenny I. Shen, Jeffrey Perl
Journal: Journal of the American Society of Nephrology (2024)

1UCLA David Geffen School of Medicine, Harbor-UCLA Medical Center, Torrance, California 2St. Michael's Hospital, Toronto, Ontario, Canada Correspondence: Dr. Jenny I. Shen, email: [email protected] See related article, "Race- and Ethnicity-Related Disparities in Predialysis Nephrology Care, Kidney Disease Education, and Home Dialysis Utilization," on pages XXX–XXX.
Vascular smooth muscle cell PRDM16 regulates circadian variation in blood pressure
Authors: Zhenguo Wang, Wenjuan Mu, Juan Zhong, Ruiyan Xu, Yaozhong Liu, Guizhen Zhao, Yanhong Guo, Jifeng Zhang, Ida Surakka, Y. Eugene Chen, Lin Chang
Journal: Journal of Clinical Investigation (2024)

Disruptions of blood pressure (BP) circadian variation are closely associated with an increased risk of cardiovascular disease (CVD). Thus, gaining insights into the molecular mechanisms of BP circadian variation is essential for comprehending BP regulation. Human genetic analyses suggest that PR domain-containing protein 16 (PRDM16), a transcription factor highly expressed in vascular smooth muscle cells (VSMC), is significantly associated with BP-related traits. However, the roles of PRDM16 in BP regulation are largely unknown. Here, we demonstrate that BP in VSMC-specific Prdm16 knockout (Prdm16SMKO) mice was significantly lower than that in control mice during the active period, resulting in aberrant BP circadian variation. Mesenteric artery rings from Prdm16SMKO mice showed reduced response to phenylephrine. Mechanistically, we identified adrenergic receptor alpha 1d (Adra1d) as a transcriptional target of PRDM16. Notably, PRDM16 exhibits a remarkable circadian expression pattern and regulates the expression of clock genes, particularly Npas2, which is crucial for BP circadian variation regulation. Consequently, PRDM16 deficiency in VSMC causes disrupted BP circadian variation through reduced response to adrenergic signaling and clock gene regulation. Our findings offer substantial insights into the intricate molecular pathways that govern circadian fluctuations in BP.
Genotype-First Analysis in an Unselected Health System–Based Population and Phenotypic Severity of COL4A5 Variants
Authors: McKenzie Zellers, Kaushal Solanki, Melissa A. Kelly, Karyn M. Murphy, Kyle Retterer, H. Les Kirchner, Ion Dan Bucaloiu, Bryn Moore, Tooraj Mirshahi, Alexander R. Chang
Journal: Journal of the American Society of Nephrology (2024)

Background: Our knowledge of X-linked Alport Syndrome comes mostly from selected cohorts with more severe disease. Methods: We examined the phenotypic spectrum of X-linked Alport Syndrome in males and females with a genotype-based approach using data from the Geisinger MyCode DiscovEHR study, an unselected health system-based cohort with exome sequencing and electronic health records. Patients with COL4A5 variants reported as pathogenic or likely pathogenic in ClinVar, or protein-truncating variants, were each matched with up to 5 controls without COL4A3/4/5 variants by sociodemographics, diabetes diagnosis, and year of first outpatient encounter. Phenotypes examined included dipstick hematuria, bilateral sensorineural hearing loss, proteinuria, decreased estimated glomerular filtration rate, and kidney failure. Results: Out of 170,856 patients, there were 29 hemizygous males (mean age 52 y [SD 20]) and 55 heterozygous females (mean age 59 y [SD 19]) with a pathogenic/likely pathogenic COL4A5 variant, including 48 with the hypomorphic variant p.Gly624Asp. Overall, penetrance (having any Alport Syndrome phenotypic feature) was highest for non-p.Gly624Asp variants (males: 94%, females: 85%), intermediate for p.Gly624Asp (males: 77%, females: 69%), compared to controls (males: 32%; females: 50%). The proportion with kidney failure was highest for males with non-p.Gly624Asp variants (44%), intermediate for males with p.Gly624Asp (15%) and females with non-p.Gly624Asp variants (10%), compared to controls (males: 3%, females 2%). Only 47% of individuals with COL4A5 had completed albuminuria screening, and a minority were taking renin-angiotensin aldosterone system inhibitors. Only 38% of males and 16% of females had a known diagnosis of Alport Syndrome or thin basement membrane disease. Conclusions: Using a genotype-first approach, we show that men and women with X-linked Alport Syndrome are at higher risk of related phenotypic features with a wider spectrum of severity than has been described previously and variability by genotype.
Waterborne Disease Outbreaks Associated with Splash Pads — United States, 1997–2022
Authors: Hannah Lawinger, Amina Khan, Colleen Lysen, Marydale Oppert, Vince R. Hill, Jonathan S. Yoder, Virginia A. Roberts, Mia C. Mattioli, Michele C. Hlavsa
Journal: MMWR Surveillance Summaries (2024)

Splash pads are recreational interactive water venues that spray or jet water on users. Splash pads are intended for children aged <5 years and designed so that water typically does not collect in areas accessible to users, thereby minimizing the risk for drowning. Splash pads were first found to be associated with waterborne disease outbreaks in 1997.
Challenges of Surveillance in Implementing Nonoperative Management for Rectal Cancer
Authors: Bailey K. Hilty Chu, Anthony Loria, Totadri Dhimal, Xueya Cai, Shan Gao, Yue Li, Larissa K. Temple, Fernando Colugnati, Paula Cupertino, Erika E. Ramsdale, Fergal J. Fleming
Journal: JAMA Network Open (2024)

Importance Close surveillance for detection of local tumor regrowth is critical for patients opting for nonoperative management after neoadjuvant therapy for rectal cancer. However, there are minimal data regarding the feasibility and adherence to National Comprehensive Cancer Network (NCCN) surveillance guidelines for these patients. Objective To determine adherence rates to NCCN-recommended surveillance in patients undergoing nonoperative management for rectal cancer. Design, Setting, and Participants This retrospective cohort study included patients treated at a single academic center (University of Rochester, Rochester, New York) from 2012 to 2023, with analysis completed from March through May 2024. Patients with clinical stage I to III rectal cancer who underwent treatment with neoadjuvant therapy, achieved a clinical complete response (or initially near complete clinical response), and elected for nonoperative management were enrolled. Exposure Achievement of recommended surveillance. Main Outcomes and Measures The primary outcome was adherence to surveillance guidelines for patients undergoing nonoperative management for rectal cancer. Secondary outcomes included assessment of oncologic outcomes stratified by adherence to surveillance. Results Eighty-five patients (54 male [63.5%]; median [IQR] age, 63.0 [54.0-73.0] years) were managed nonoperatively and followed for a median of 4.04 years (95% CI, 3.17-4.58 years). The 5-year overall survival was 82.3% (95% CI, 71.8%-94.5%), the 5-year disease-specific survival was 95.1% (95% CI, 89.6%-100.0%), the rate of local regrowth was 24.7% (21 patients), and the rate of distant metastases was 12.9% (11 patients). Among the 77 patients with more than 6 months of follow-up in their first year of surveillance, only 39.0% of patients (30 patients) achieved NCCN-recommended surveillance in the first year, and this decreased to 15.0% (3 patients) by year 5. However, the time to local regrowth and distant metastasis were similar regardless of the level of surveillance. Conclusions and Relevance In this cohort study of patients with rectal cancer undergoing surveillance after nonoperative management, most did not achieve NCCN-recommended guidelines, although outcomes were not associated with surveillance intensity. This highlights the need for prospective evaluation of a surveillance regimen that is both feasible for patients and health care systems increasingly using nonoperative management. In addition, studies are warranted to explore patient preferences in rectal cancer care and to identify barriers to optimal surveillance.